# ARS PHARMACEUTICALS INC (SPRY)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/SPRY/

- Reporting holders: 4
- Reported value: $292.6K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Norman Fields, Gottscho Capital Management, LLC](https://holderbook.com/funds/1352449-norman-fields-gottscho-capital-management-llc/) | $273.2K | 63,380 | 0.1% | 3 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $9.1K | 2,108 | 0.0% | 7 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $6.9K | 1,594 | 0.0% | 9 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $3.5K | 808 | 0.0% | 12 |
| [CX Institutional](https://holderbook.com/funds/1737089-cx-institutional/) | $12 | 2,890 | 0.0% | 5 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 4 | $292.6K |
| Q2 2026 | 211 | $769.5M |
| Q1 2026 | 202 | $780.9M |
| Q4 2025 | 193 | $1.1B |
| Q3 2025 | 192 | $862.5M |
| Q2 2025 | 194 | $1.5B |
| Q1 2025 | 185 | $967.0M |
| Q4 2024 | 168 | $758.6M |
| Q3 2024 | 152 | $952.5M |
| Q2 2024 | 116 | $553.3M |
| Q1 2024 | 116 | $622.0M |
| Q4 2023 | 100 | $374.4M |